Is Dacomitinib on the market?

On September 27, 2018, The U.S. Food and Drug Administration (FDA) approved dacomitinib (Dacomitinib) tablets for the treatment of metastatic non- First-line treatment of patients with small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutation as detected by an FDA-approved test, marketed under the trade name VIZIMPRO.

Dacomitinib was shown to significantly improve patient survival time without worsening the disease. Compared with patients who took gefitinib, those who took dacomitinib lived six months longer without worsening of their disease. Although dacomitinib causes more side effects than gefitinib, these are considered manageable. Therefore, dacomitinib has also been approved by the European Medicines Agency (EMA). DacomitinibThe original drug has also been approved by the State Food and Drug Administration in 2019 for domestic marketing, and subsequently entered the scope of Class B medical insurance.

Dacomitinib Original drug marketed in China, common specifications15mg*30 tablets may be priced at more than 1,000 yuan per box; European version of dacomitinib original drug sold overseas, specifications45mg*30 tablets may be priced at more than 20,000 yuan per box (the price may fluctuate due to exchange rates). Currently, there are cheaper generic drugs of dacomitinib sold overseas. Their pharmaceutical ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 45mg*30 tablets produced by a Lao pharmaceutical factory may be around a few hundred yuan per box (the price may fluctuate due to exchange rate effects).